T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
Shablak, A, Hawkins, R, Rothwell, D and Elkord, E 2009, 'T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.' , Clinical Cancer Research, 15 (21) , pp. 6503-6510.
- Published Version
Restricted to Repository staff only
Download (363kB) | Request a copy
Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.
|Themes:||Health and Wellbeing|
|Schools:||Schools > School of Environment and Life Sciences|
|Journal or Publication Title:||Clinical Cancer Research|
|Publisher:||American Association for Cancer Research|
|Depositing User:||E Elkord|
|Date Deposited:||12 Oct 2011 10:53|
|Last Modified:||05 Apr 2016 18:00|
Actions (login required)
|Edit record (repository staff only)|